Funding for this research was provided by:
national cancer institute (1R01CA249568-01, P30CA014236)
Received: 29 September 2021
Accepted: 19 October 2021
First Online: 18 November 2021
: This study was approved by the Duke Institutional Review Board. Study participants provided written informed consent.
: N/A: This is paper describes a protocol.
: The authors report no financial or non-financial interests related to the current work.Unrelated to the current work, Dr. Zullig reports research funding from Proteus Digital Health and the PhRMA Foundation, as well as consulting from Novartis and Pfizer. Dr. Zafar reports employment and stock from Shattuck Labs (to his spouse), serving on advisory boards for Vivor, LLC (uncompensated) and Cancer Support Community (uncompensated), serving on the Board of Directors ffor Family Reach (uncompensated), and being a board member for WCG IRB. Dr. Zafar also reports research funding from AstraZeneca and consulting for RTI, McKesson, Quintiles, and Change Healthcare. Dr. Dent reports research funding from Novartis.